Fispemifene
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | HM-101 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H27ClO3 |
Molar mass | 422.95 g·mol−1 |
3D model (JSmol) | |
| |
|
Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]
See also
References
- ^ a b c "Fispemifene". AdisInsight. Springer Nature Switzerland AG.
- ^ Cano A, Calaf i Alsina J, Duenas-Diez JL (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2.
- ^ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3.
External links
Categories:
- Articles with short description
- Short description matches Wikidata
- Chemical pages without DrugBank identifier
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Use dmy dates from April 2017
- Primary alcohols
- Organochlorides
- Progonadotropins
- Selective estrogen receptor modulators
- Triphenylethylenes
- All stub articles
- Genito-urinary system drug stubs